Scientific Program

(preliminary, as of March 2023)

Wednesday, May 31, 2023

17h00 – 18h00

General Assembly E-ISFA

Thursday, June 1, 2023

08h30 – 08h55

Opening Ceremony
Chairs:
B. Hohenstein, ISFA President (DE), W. Ramlow, E-ISFA President (DE)

09h00 – 10h20

Apheresis around the world I:
Country specific aspects

Kurt Derfler (Institute ATHOS, Vienna, AT)

Kahlid Al Rasadi (Sultan Qaboos University, Biochemistry, OM)
Organization and national activities of therapeutic apheresis in Oman

Ken Yamaji (Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, JP)

Amber Sanchez (University of California San Diego, US)
Organization and national activities of therapeutic apheresis in the USA

Lipid disorders and CVD I:
Lipid disorders – it all starts with the measurement

Winfried März (SYNLAB Akademie, DE)
Dyslipidemia – it all starts with a correct measurement

Johanna Schachtl-Riess (Medical University of Innsbruck, AT)
Lipoprotein(a) – from genetics to phenotype

Jeffrey Kroon (University of Amsterdam, NL)
Evidence for a strong pro-inflammatory potential of lipoprotein(a)

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Lipoprotein-apheresis and its effect on HDL functionality

10h20 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h05

Apheresis around the world II:
South East Asian perspectives

Sasitorn Siritho (Bumrungrad International Hospital, TH)
Systematic review of TPE practices in central neuroimmunological disorders: evolving concepts in South East Asia

Lu Fiong Hiew (Kuala Lumpur Hospital, MY)
Uniting the world through TPE: SEATPEC challenges & potential future collaborations

Nghia Hoang (Military Hospital, Ho Chi Minh, VN)
TPE and its challenges in Vietnam

Dhayalen Krishnan (Kuala Lumpur General Hospital, MY)
Introduction to SEATPEC, best practices and TPE guidelines in South East Asia

Registries
Registries as research tools in apheresis

Christian Schumann (MVZ Kempten, DE)
CACOV – an apheresis registry for severely ill acute COVID patients

Bernd Hohenstein (Nephrologisches Zentrum Villingen-Schwenningen, DE)
The German Long-Covid Apheresis Register – design and first experiences

Wanja Bernhardt (Centre for Hypertension, Kidney and Metabolic diseases, Hanover, DE)
The German Lipoprotein Apheresis Register – a specific analysis of Lp(a) apheresis patients

Kahlid Al Rasadi (Sultan Qaboos University, Biochemistry, OM)
The Gulf region FH registry

12h05 – 12h30

Break and Poster Viewing

12h30 – 13h45

Lunch Symposium –
Miltenyi Biotec

Lunch Symposium –
Daiichi Sankyo

Apherese-Weiterbildung in deutscher Sprache: Teil 1

13h45 – 14h00

Break and Poster Viewing

14h00 – 15h15

Apheresis around the world III:
Current updates & issues (from the American Society for Apheresis – ASFA)

Joseph (Yossi) Schwartz (Ichan School of Medicine at Mount Sinai, New York, US)
Growing variations in collections for further manufacturing

Betty Doggett (Carter BloodCare, Laird Hill, US)
Vascular access – issues & resolutions

Nicole Aqui (Perelman School of Medicine, University of Pennsylvania, US)
ASFA Guidelines for Therapeutic Apheresis

Autoimmune diseases I
Neuroimmune diseases and immunomodulation

Wolfgang Köhler (Leipzig University, DE)
The role of apheresis therapy in MS and NMOSD

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Immunomodulatory effect associated with therapeutic plasmapheresis

N. N.

Begrüßung

Jens Ringel (DE)

Apherese, eine erfolgreiche Geschichte

Apherese ist nicht gleich Apherese

Ultima ratio bei Lipoproteinstörungen

15h15 – 15h30

Coffee Break & Poster Viewing

15h30 – 17h30

Apheresis around the world IV
Apheresis therapy in Japan

Apheresis in critical care medicine

Jan Stange (University Medical Center Rostock, DE)
Recent developments in the field of extracorporeal albumin detoxification (ECAD) for liver support

Gerd Klinkmann (University Medical Center Rostock, Department of Anesthesiology and Intensive Care Medicine, DE)
Extracorporeal immune cell therapy in sepsis

Steffen Mitzner (University Medical Center Rostock, DE)
Cytokine adsorption in sepsis and septic shock – still under debate

Amber Sanchez (University of California San Diego, US)
How to combine multiple extracorporeal systems in critical care

Sascha David (Zurich University Hospital, CH)
TPE in septic shock: to remove and replace

Apherese-Weiterbildung in deutscher Sprache: Teil 2

Apherese mehr als nur Lipidreduktion

Heparin oder Citrat zur Antikoagulation

Pflegerische Aspekte in der Apheresebehandlung von
Long/Post-Covid Patienten

Pflegerische Aspekte in der Apheresebehandlung von Kindern

17h30 – 19h30

Welcome Reception & Poster Session

Friday, June 2, 2023

08h30 – 09h50

Apheresis around the world V:
Country specific aspects

Shamanna Iyengar (Manipal Academy of Higher Education, IN)
On the way to establish a lipid apheresis program in India by Lipid Association of India (LAI)

Ahmed Alsaraff (KW)
LDL apheresis in homozygous familial hypercholesterolemia in Kuwait

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Cross sectional analysis of apheretical therapies in Italy

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Organization and national activities of therapeutic apheresis in France

Guest workshop:
Association of German Dialysis Centers (DN e. V.)

Georg Schlieper (Dialysis Centre Hanover, DE)
Is there a role for immunoadsorption in Post Covid?

Volker Schettler (Center of Nephrology, Dialysis and Apheresis, Göttingen, DE)
The German Lipoprotein Apheresis Registry (GLAR) – Summary of the tenth annual report

Jan Kielstein (Braunschweig Hospital, DE)
From sepsis to COVID – apheresis therapy in critical care medicine

09h00 – 12h00

Apherese-Weiterbildung in deutscher Sprache: Anwenderworkshop Teil 1

09h50 – 10h20

Coffee Break, Exhibition & Poster Viewing

10h20 – 12h10

COVID-19 I:
Apheresis in COVID-19 and its complications

Carmen Scheibenbogen (Charité – Universitätsmedizin Berlin, DE)
Long-term consequences of COVID and current therapeutic perspectives

Beate Jäger (DE)
Long COVID – why apheresis therapy could make the difference

Harald Matthes (Havelhöhe Community Hospital, Berlin, DE)
Is apheresis therapy an option for neuroinflammatory Post-vaccination syndrome?

Panel discussion – pro and contra

Lipid disorders and CVD II:
Apheresis targeting microcirculation and inflammation

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Apheresis to improve rheology – indications and results

Dusit Lumlertgul (Faculty of Medicine, Chiang Mai, TH)
Double filtration plasmapheresis (DFPP) to improve microcirculation

Jan Torzewski (Allgäu Hospital Network, Immenstadt, DE)
CRP – from laboratory parameter to key player of inflammation

Shuzo Kobayashi (Shonan Kamakura General Hospital, JP)
A new adsorber for the treatment of critical limb ischemia

Rosita Bihariesingh et al. (Academic Hospital Paramaribo Suriname)
First-in-Man: Plasmapheresis with a novel blood separation device in hypertriglyceridemia and acute pancreatitis

12h10 – 12h30

Lunch Break, Exhibition & Poster Viewing

12h30 – 13h45

Lunch Symposium – Fresenius Medical Care

Lunch Symposium

13h45 – 14h00

Lunch Break, Exhibition & Poster Viewing

14h00 – 15h20

COVID-19 II:
Treatment approaches in COVID and its consequences

Wladimir M. Szpirt (Rigshospitalet, Copenhagen, DK)
Plasma exchange utilizing convalescent plasma in severe COVID patients

Sebastian Koball (University Medical Center Rostock, DE)
How to evaluate apheresis efficacy in patients suffering from Long COVID?

Gunnar Bücker (Nephrology group practice, Osnabrück, DE)
HELP apheresis in Long COVID – a practice report

Julia Weinmann-Menke (Universitätsmedizin Mainz, DE)

New guidelines and developments:
Technical developments and recommendations

Uwe H. Wallstab (mdXperts GmbH, Cologne, DE)
Relevance of sufficient clinical safety and performance data to maintain CE mark of apheresis devices

Viktoria Weber (Danube University Krems, AT)
Influence of the column surface on therapeutic apheresis – an old issue but new developments are rising

Volker Witt (Paediatric Hospital “St. Anna”, Vienna, AT)
ASFA Guidelines in therapeutic apheresis – the new issue 2023

Kensuke Owari et al. ( TAGCyx Biotechnologies, Inc., Tokyo, Japan)
Development of next generation apheresis using artificial base DNA Aptamer

Lipid disorders and CVD III: Workshop German Lipid League

Oliver Weingärtner (University Hospital Jena, DE)
A nationwide initiative to reach lipid targets

Anja Vogt (Ludwig Maximilians University Hospital, Munich, DE)
Novel lipid lowerting medications – current status and future perspectives

Ulrich Julius (University Hospital Dresden, DE)
DIAMOND study – a comparison between plasma and whole blood lipoprotein apheresis

13h00 – 15h30

Apherese-Weiterbildung in deutscher Sprache: Anwenderworkshop Teil 2

 

15h20 – 15h45

Coffee Break, Exhibition & Poster Viewing

15h45 – 17h30

Lipid disorders and CVD IV:
Treatment modalities in clinial practice

Wanja Bernhardt (Dialysis Centre Hanover, DE)
Long-term experience of Lp(a) apheresis in outpatient care

Tiziana Sampietro (National Research Council Institute of Clinical Physiology, Pisa, IT)
The role of lipoprotein apheresis on hypercholesterolemia and L(pa) – the Pisa experience

Ulrich Julius (University Hospital Dresden, DE)
Cardiovascular events before and during apheresis treatment – a detailed analysis for vascular regions

Jannecke Mulder (NL)
Quality of life in Dutch hoFH patients

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Development of novel drug for primary chylomicronemia by using antisense

Autoimmune diseases II:
Apheresis in rheumatologic and inflammatory bowel disease

Andreas Kronbichler (Medical University Innsbruck, AT)
Apheresis therapy in autoimmune vasculitides – PEXIVAS is not the end

Yoshihiro Endo
(Shiga University of Medical Science, Otsu, JP)
Novel hemo-adsorbent for ulcerative colitis in Japan

Makoto Naganuma (Keio University School of Medicine, Tokyo, JP)
Recent trends of apheresis treatment for inflammatory bowel disease

Ken Yamaji (Juntendo University, Tokyo, JP)
Is apheresis therapy still an option in rheumatic diseases?

Andreas Goebel (University of Liverpool, UK)
Introducing a study design to evaluate immunoadsorption in fibromyalgia

Apherese-Weiterbildung
in deutscher Sprache: Workshop Vaskulärer Zugang

tba.

18h30 – 23h00

Congress Dinner

Saturday, June 3, 2023

08h30 – 10h15

Autoimmune diseases III
Apheresis for renal diseases

Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Apheresis and desensitization before kidney transplantation

Benjamin Savenkoff (CHR Metz-Thionville, FR)
The role of apheresis therapy in glomerulopathies

Vladimir Kuklin (NO)
Title tba.

Wladimir Szpirt (Rigshospitalet, Copenhagen, DK)
An evolution in treatment of anti GBM nephritis – plasma exchange or imlifidase?

Lipids and CVD V:
Pleiotropic and other expected windfall gains

Grit Waitz (BioArtProducts, Rostock, DE)
Cardiometabolic risk assessment – the impact of comorbidities

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Lipoprotein apheresis for the treatment of familial hypercholesterolemia in Japan

Takafumi Ito (JP)
Efficacy and safety of LDL apheresis for the treatment of cholesterol crystal embolism

N. N.

10h15 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h30

Future perspectives of apheresis therapy
The future perspectives of apheresis

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Future perspectives in apheresis therapy – lipoprotein apheresis

Jan Kielstein (Braunschweig Hospital, DE)
Title tba.

Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Future perspectives in apheresis therapy – renal diseases and transplantation

Reinhard Klingel (Apheresis Research Institute, Cologne, DE)
Future perspectives in apheresis therapy – immune-mediated conditions

Pediatric apheresis
Apheresis in children and adolescent patients

Marc Fila (CHU Montpellier, FR)
Efficacy and tolerance of PLEX/IA in peadiatric neurology: results of a nationwide study in France

Wolfgang Ries (Diako Hospital Flensburg, DE)
Severe chronic fatigue syndrome (ME/CFS) in children – when is immunoadsorption justified?

Julia Thumfart (Charité – Universitätsmedizin Berlin, DE)
Apheresis therapy for pediatric neurological diseases – a German perspective

Volker Witt (Paediatric Hospital “St. Anna”, Vienna, AT)
Title tba.

12h30 – 13h00

Closing Ceremony & Awards Presentation

13h00

Farewell

Cookie Consent with Real Cookie Banner